Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.33 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.33 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | IL1B | P01584 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770784 | 0.96 | SYK (0.38) | CCNT1SYKVCPNUDT1IL1B | |
| SCHEMBL19970019 | 0.95 | MAPK3 (0.38) | CCNT1SYKMAPK3NUDT1IL1B | |
| SCHEMBL19970021 | 0.95 | MAPK3 (0.38) | CCNT1SYKMAPK3NUDT1IL1B | |
| SCHEMBL19970024 | 0.95 | MAPK3 (0.38) | CCNT1SYKMAPK3NUDT1IL1B | |
| SCHEMBL23770790 | 0.86 | IL1B (0.32) | CCNT1IL1BCCNKCCNE1CDK2 | |
| SCHEMBL23770573 | 0.86 | CCNT1 (0.36) | CCNT1PIM1IL1BMEN1CYP1A2 | |
| SCHEMBL23770848 | 0.86 | IL1B (0.33) | IL1BCTSA | |
| SCHEMBL23770706 | 0.85 | SMN1; SMN2 (0.36) | CCNT1PIM1MEN1TSHRKMT2A | |
| SCHEMBL19951335 | 0.85 | SYK (0.42) | SYKVCPNUDT1IL1BEPHX2 | |
| SCHEMBL19951403 | 0.84 | MAPK3 (0.44) | CCNT1DYRK3MAP4K4ERBB2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | CCNT1 4170/4885SYK 689/4885DYRK3 2450/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | CCNT1 4170/4885SYK 689/4885DYRK3 2450/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | CCNT1 4170/4885SYK 689/4885DYRK3 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.